|
| |
| The Early Stage Company portion of the 2010 installment of the Bioscience Discovery Evaluation Grant Program (House Bill 1001) is designed to spur economic growth in the state of Colorado and/or aid new companies born out of Colorado institutions. The early-stage bioscience company grant will award a maximum of $250,000 to companies whose technology is licensed from a qualified research institution in Colorado. The grant is designed to support the commercialization of therapeutic or diagnostic products; devices, or instruments to improve human health; bioscience technologies that improve agriculture; or biofuels. The selection process will be carried out directly through the Colorado Office of Economic Development and International Trade (OEDIT).
|
| |
Eligibility Overview
- Licensed IP from a qualified research institution
- Less than 5 million dollars in investments for the life of the company (from non-founder investors including third-parties and grants)
- Less than 20 employees
- Headquarters housed in Colorado
- Share/Cost Ratio (Matching Funds) is 1:1
|
| |
| Timeline and Deadlines: |
| |
| OEDIT Application Deadline |
|
Grant Decisions |
First Cycle:
September 15, 2010 |
|
October 30, 2010 |
| |
|
|
Second Cycle:
January 31, 2010 |
|
March 15, 2011 |
|
| |
* Deadlines for requesting a letter of support for the additional cycles will be
determined at a later date. |
| |
Application Insights
The review committee will be looking for projects with commercial potential and scientific merit which create jobs in Colorado. Applicants are strongly encouraged to utilize local incubators as applications that specify such assistance will be favored. It is important to note that the review committee may recommend a grant for an amount other than that requested in the application. Additional factors include reasonable and achievable timelines and budgets, strong IP, simple rationale for the part of the market you intend to address, as well as how you will be successful in penetrating that market compared to that of the competition. Minor note: areas of application considered trade secrets, privileged information, or confidential is clearly marked as such, but the entire application cannot be marked confidential. |
| |
| |
|
|
|
